> FoldRx Pharmaceuticals has raised $43 million in its second round of venture capital. Report
> Bio-Matrix Scientific Group has entered into a letter of intent to sell its wholly owned subsidiary and operating entity to Tasco Holdings International. Release
> In a new sign of the generic drug price war unfolding in Europe, Stada Arzneinmittel has announced it will slash prices on some generics by 50 percent. Report
> Pfizer says it will cuts costs in Japan 12 percent this year without slashing jobs. Report
> Samaritan Pharmaceuticals has reported positive preliminary results for a Phase II trial of its HIV therapy. Release
> Parata Systems has inked a deal to buy virtually all of the assets in McKesson's automated prescriptions systems division while McKesson becomes Parata's sole third-party distributor in the U.S. The deal is expected to close next month. Only about one in ten pharmacies in the U.S. uses an automated system for prescription drugs, but that number is expected to accelerate rapidly as the industry deals with a shortage of pharmacists. Report
> Beckman Coulter announced today it has entered into an agreement to sell the company's minority interest in Agencourt Personal Genomics, a developer of next generation genetic analysis technologies. Release
> Teva has won tentative FDA approval for a generic version of Merck's Cozaar for high blood pressure. Final approval is expected in 2010, when patent protection expires. Report
> Antares Pharma and Eli Lilly have filed for patent protection on a needle-free injection device. Report
> ISTA Pharmaceuticals is launching two Phase III trials of its experimental drug Xibrom for pain and inflammation. Release
> BioE is investing in the stem cell work of a group of University of Newcastle researchers. Report
> CuraGen has launched a second Phase II trial of Velaphermin. Release
And Finally… Depression falls heavily on the aged, who are far less likely to seek treatment than the young. Article